← brief for 2026-09-16 · Regeneration & devices

Light-activated CRISPR/dCas9 nanomedicine for programmable control of renal fibrosis.

Key takeaways

Scientists created a light-activated gene tool in the test tube and in mice that can turn off scarring signals in the kidney. This is very early work — no humans have been treated yet, and it may be many years before this approach is ready for testing in people.

Who did this work

Taha BA · Addie AJ · Haider AJ · Ibnaouf K · Apsari R · Arsad N

Source

Article · PubMed, fibrosis reversal · 2026 Sep 13
https://pubmed.ncbi.nlm.nih.gov/42735456/